Further evidence for the lack of correlation between the breakpoint site within M-BCR and CML prognosis and for the occasional involvement of p53 in transformation.

[1]  M. Cline,et al.  The molecular basis of leukemia. , 1994, The New England journal of medicine.

[2]  J. Melo,et al.  P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? , 1994, Leukemia.

[3]  Nanxin Li,et al.  BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein , 1993, Cell.

[4]  K. Tanaka,et al.  Influence of M-BCR breakpoint sites on the duration of chronic phase in 100 patients with chronic myelocytic leukemia. , 1993, Cancer genetics and cytogenetics.

[5]  Z. Estrov,et al.  Chronic Myelogenous Leukemia : A Concise Update , 2003 .

[6]  M. Baccarani,et al.  The type of BCR/ABL junction does not predict the survival of patients with Ph1‐positive chronic myeloid leukaemia , 1993, British journal of haematology.

[7]  D. Lane.  A death in the life of p53 , 1993, Nature.

[8]  F. Mitelman,et al.  Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia. , 1993, Leukemia.

[9]  K. Ishizaki,et al.  Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. , 1992, Cancer research.

[10]  M. Negrini,et al.  A new chromosomal breakpoint in Ph positive, bcr negative chronic myelogenous leukemia. Report of a case. , 1992, Cancer genetics and cytogenetics.

[11]  K. Mills,et al.  Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukaemia patients with a breakpoint around exon 14 (b3) of the BCR gene. , 1991, Leukemia.

[12]  K. Mills,et al.  Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. , 1991, Blood.

[13]  A. Berrebi,et al.  p53 in chronic myelogenous leukemia in acute phase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  O. Witte,et al.  BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner , 1991, Cell.

[15]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[16]  M. Bar‐eli,et al.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. , 1991, The Journal of clinical investigation.

[17]  O. Witte,et al.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias , 1991, Molecular and cellular biology.

[18]  A. Hagemeijer,et al.  Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML. , 1991, Cancer genetics and cytogenetics.

[19]  D. Schaid,et al.  The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia. , 1990, Leukemia.

[20]  G. Saglio,et al.  New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. , 1990, Blood.

[21]  Y. C. Chen,et al.  Chromosome and bcr rearrangement in chronic myelogenous leukaemia and their correlation with clinical states and prognosis of the disease , 1990, British journal of haematology.

[22]  S. Morris,et al.  Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase [see comments] , 1990 .

[23]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[24]  P. Martiat,et al.  The position of the M‐BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukaemia , 1990, British journal of haematology.

[25]  K. Mills,et al.  Further evidence that the site of the breakpoint in the major breakpoint cluster region (M-bcr) may be a prognostic indicator. , 1989, Leukemia.

[26]  V. Rotter,et al.  Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. , 1989, Blood.

[27]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[28]  P. Gascón,et al.  Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia. , 1989, American journal of human genetics.

[29]  T. Soma,et al.  No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients. , 1989, Leukemia.

[30]  J. Bosco,et al.  Clinical stage of chronic granulocytic leukaemia and BCR breakpoint location in South‐East Asian patients , 1989, British journal of haematology.

[31]  D. Przepiorka.  Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with disease phase or prognosis. , 1988, Cancer genetics and cytogenetics.

[32]  K. Mills,et al.  The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. , 1988, Blood.

[33]  R. Silver,et al.  The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. , 1988, Leukemia.

[34]  G. Saglio,et al.  Variability of the molecular defects corresponding to the presence of a Philadelphia chromosome in human hematologic malignancies. , 1988, Blood.

[35]  R. Kurzrock,et al.  Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. , 1988, Blood.

[36]  R. Gale,et al.  Rapid progress in chronic myelogenous leukemia. , 1988, Leukemia.

[37]  A. Grosovsky,et al.  The specificity of UV-induced mutations at an endogenous locus in mammalian cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Mears,et al.  CML patients in blast crisis have breakpoints localized to a specific region of the BCR , 1987 .

[39]  M. Greaves,et al.  Molecular lesion in chronic granulocytic leukemia is highly conserved despite ethnic and geographical variation. , 1987, Leukemia.

[40]  J. Mears,et al.  Frequent and extensive deletion during the 9,22 translocation in CML. , 1986, Blood.

[41]  G. Daley,et al.  The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. , 1986, Science.

[42]  J. Mears,et al.  Variable breakpoints on the Philadelphia chromosome in chronic myelogenous leukemia. , 1985, Blood.

[43]  E. Canaani,et al.  An 8-kilobase abl RNA transcript in chronic myelogenous leukemia. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[45]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[46]  J. Stephenson,et al.  Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia , 1983, Nature.

[47]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[48]  E. Southern.  Detection of specific sequences among DNA fragments separated by gel electrophoresis. , 1975, Journal of molecular biology.

[49]  S. Izhar.  Cell Budding and Fission in Microspores of Petunia , 1973, Nature.

[50]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.